The report of the committee is yet to be submitted, State Minister of Chemicals and Fertilizers Hans Raj Gangaram Ahir informed Parliament.
"Government in the Ministry of Health and Family Welfare has set up a core committee for revision of National List of Essential Medicine (NLEM) 2011 in which both the Department of Pharmaceutical and NPPA are represented," said Ahir.
There are 680 drug formulations related to 348 bulk drugs listed in NLEM by National Pharmaceutical Pricing Authority (NPPA).
"To address the issue of price negotiation mechanism for patented drugs, an inter-ministerial committee of joint secretaries has been set up on November 7, 2011 to look into the issues and to suggest ways and means to fix prices of patented drugs in the country," Ahir informed.
He further informed that the government has received two requests by the private players to manufacture patented drugs under the compulsory licensing and in which drug maker Natco's plea has been approved by the Controller General of Patents designs and Trade Mark (CGPDTM).
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
